Articles · HRT
HRT and Breast Cancer Risk
One 2002 study scared millions of women off hormones. The fuller picture is more mixed.
Sourced from peer-reviewed research and clinical guidelines, cited at the end of this article. How we write about your body.
In 2002, a large American trial called the Women’s Health Initiative (WHI) reported that hormone replacement therapy raised breast cancer risk. The news went around the world. Within a year, prescribing rates in the US dropped by more than 30%.[1]
Twenty years on, the picture is more complicated. The study looked at the wrong age group. It used a drug combination that most guidelines no longer pick first. And it reported the risk in the way most likely to alarm people.
None of that makes the concern fake. But if your view of HRT was shaped by 2002 headlines, you may be missing part of the story.
What the WHI Actually Studied
The WHI was not built to study perimenopause. It was built to test whether HRT lowered heart disease in older postmenopausal women.[2] A few facts about who took part:
- Average age: 63[2]
- Most were more than 10 years past their last period
- The estrogen was oral conjugated equine estrogen (CEE), taken from horse urine, not the body-identical estradiol in most modern prescriptions
- The progestogen was medroxyprogesterone acetate (MPA), a synthetic
The group taking estrogen plus MPA was the one stopped early. That regimen is used by women who still have a womb. The estrogen-only group, for women who had had a hysterectomy, was not stopped for breast cancer. In fact, that group showed a trend toward lower breast cancer risk.[3]
Absolute Risk vs Relative Risk
The results were reported as relative risk. HRT users had a “26% increase” in breast cancer compared with the placebo group.[2]
Relative figures are accurate but leave out the base rate. Here are the actual numbers behind that 26%:
- Placebo group: 30 breast cancer cases per 10,000 women per year
- HRT group: 38 cases per 10,000 women per year
- Difference: 8 extra cases per 10,000 women per year
For comparison, one glass of wine a day is linked to a similar rise in absolute breast cancer risk.[4] The WHI finding was real. The way it was shared made a modest number sound like a disaster.
The Timing Hypothesis
The biggest shift in HRT research since 2002 is the “timing hypothesis.” It holds that the balance of risk and benefit depends heavily on when you start HRT relative to menopause.[5]
Women in the WHI were 63 on average and mostly a decade or more past their final period. Women who start HRT during perimenopause, or within 10 years of their last period, seem to have a very different experience.
A reanalysis of WHI data in JAMA Internal Medicine found that for women who started within 10 years of menopause, there was no meaningful rise in heart problems, and in some subgroups the risk was lower.[6] This fits lab research suggesting estrogen protects healthy blood vessels but may speed up disease in older, already-narrowed ones.[5]
The Danish Nurses’ Cohort Study followed women from around the start of menopause for 10 years. HRT users had clearly lower rates of heart attack, heart failure, and death from any cause, with no clear difference in breast cancer.[7] That came from a large study designed to test this question, not a side result.
The Progestogen Makes a Difference
The estrogen-only group in the WHI showed no rise in breast cancer. The rise was only in the estrogen-plus-MPA group.[3]
MPA is a synthetic progestogen and behaves differently from the body’s own progesterone. Later research shows the type of progestogen matters:
- Synthetic progestogens (MPA, norethisterone, levonorgestrel) are linked to a small rise in breast cancer risk in combined HRT.[8]
- Micronised progesterone (body-identical, sold as Utrogestan or Prometrium) appears to carry lower risk, though the evidence is still building.[8]
The E3N study followed French women for almost nine years. Estrogen with micronised progesterone was not linked to higher breast cancer risk. Estrogen with synthetic progestogens was.[8]
UK guidelines (NICE 2023) and the British Menopause Society now recommend micronised progesterone as the preferred progestogen when HRT is used.[9]
What Current Guidelines Say
The North American Menopause Society, the British Menopause Society, and the International Menopause Society now hold broadly similar positions.
For healthy women under 60, or within 10 years of menopause, who have symptoms that bother them, the benefits of HRT usually outweigh the risks.[9][10] Those benefits include better quality of life, symptom relief, heart protection when started early, stronger bones, and possibly some cognitive benefit.
The extra breast cancer risk from HRT is small. It depends on how long you use it and which progestogen you take. It is similar in size to lifestyle factors that get far less attention.[4]
For women with a personal history of hormone-receptor-positive breast cancer, HRT is still not advised while the evidence stands.[9] For women with a family history, work through the decision with an oncologist or a menopause specialist.
Your Own Risk
The WHI finding was not made up. There is a small rise in breast cancer risk with combined HRT, mainly with synthetic progestogens, in women who use it for five years or more. That is worth weighing.
But the way that risk was read, and told to the public, in 2002 was poor. The study used the wrong age group, the wrong drugs, and the most frightening framing available.
If you are in perimenopause, your symptoms are affecting your life, and you are not in a high-risk group for breast cancer, the evidence supports a real conversation with your doctor. The question is not whether HRT is safe in the abstract. It is whether, for you, at your age, with your history, and with today’s formulations, the benefits outweigh the risks. That answer is personal, and it is often yes.
References
[1] Hersh, A. L., Stefanick, M. L., Stafford, R. S. (2004). National use of postmenopausal hormone therapy: Annual trends and response to recent evidence. JAMA, 291(1), 47-53. https://doi.org/10.1001/jama.291.1.47
[2] Rossouw, J. E., Anderson, G. L., Prentice, R. L., et al. (2002). Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA, 288(3), 321-333. https://doi.org/10.1001/jama.288.3.321
[3] Anderson, G. L., Limacher, M., Assaf, A. R., et al. (2004). Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. JAMA, 291(14), 1701-1712. https://doi.org/10.1001/jama.291.14.1701
[4] Allen, N. E., Beral, V., Casabonne, D., et al. (2009). Moderate alcohol intake and cancer incidence in women. Journal of the National Cancer Institute, 101(5), 296-305. https://doi.org/10.1093/jnci/djn514
[5] Manson, J. E., Clarkson, T. B., Karas, R. H. (2006). Effects of conjugated equine estrogen on the cardiovascular system: Findings from the Women’s Health Initiative. Arteriosclerosis, Thrombosis, and Vascular Biology, 26(8), 1700-1707.
[6] Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353-1368. https://doi.org/10.1001/jama.2013.278040
[7] Schierbeck, L. L., Rejnmark, L., Tofteng, C. L., et al. (2012). Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ, 345, e6409. https://doi.org/10.1136/bmj.e6409
[8] Fournier, A., Berrino, F., Clavel-Chapelon, F. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103-111. https://doi.org/10.1007/s10549-007-9523-x
[9] NICE Guideline NG23. (2023). Menopause: Diagnosis and Management. National Institute for Health and Care Excellence. https://www.nice.org.uk/guidance/ng23
[10] The NAMS 2022 Hormone Therapy Position Statement Advisory Panel. (2022). The 2022 hormone therapy position statement of The Menopause Society. Menopause, 29(7), 767-794. https://doi.org/10.1097/GME.0000000000002028
Teala surfaces health patterns to help you and your doctor make informed decisions. It does not diagnose conditions or replace medical advice. Always consult a qualified healthcare professional about your symptoms and treatment.